-
- Sarah F. Hamm‐Alvarez
- University of Southern California School of Pharmacy Los Angeles
-
- Srikanth R. Janga
- University of Southern California School of Pharmacy Los Angeles
-
- Maria C. Edman
- University of Southern California School of Pharmacy Los Angeles
-
- Sara Madrigal
- University of Southern California School of Pharmacy Los Angeles
-
- Mihir Shah
- University of Southern California School of Pharmacy Los Angeles
-
- Starleen E. Frousiakis
- University of Southern California Keck School of Medicine Los Angeles
-
- Kavita Renduchintala
- University of Southern California Keck School of Medicine Los Angeles
-
- Jay Zhu
- University of Southern California Keck School of Medicine Los Angeles
-
- Seth Bricel
- University of Southern California Keck School of Medicine Los Angeles
-
- Kimberly Silka
- University of Southern California Keck School of Medicine Los Angeles
-
- Dianne Bach
- University of Southern California Keck School of Medicine Los Angeles
-
- Martin Heur
- University of Southern California Keck School of Medicine Los Angeles
-
- Stratos Christianakis
- University of Southern California Keck School of Medicine Los Angeles
-
- Daniel G. Arkfeld
- University of Southern California Keck School of Medicine Los Angeles
-
- John Irvine
- University of Southern California Keck School of Medicine Los Angeles
-
- Wendy J. Mack
- University of Southern California Keck School of Medicine Los Angeles
-
- William Stohl
- University of Southern California Keck School of Medicine Los Angeles
書誌事項
- 公開日
- 2014-06-27
- 権利情報
-
- http://onlinelibrary.wiley.com/termsAndConditions#vor
- DOI
-
- 10.1002/art.38633
- 公開者
- Wiley
この論文をさがす
説明
<jats:sec><jats:title>Objective</jats:title><jats:p>The diagnosis of Sjögren's syndrome (SS) in routine practice is largely a clinical one and requires a high index of suspicion by the treating physician. This great dependence on clinical judgment frequently leads to delayed diagnosis or misdiagnosis. Tear protein profiles have been proposed as simple and reliable biomarkers for the diagnosis of SS. Given that cathepsin S activity is increased in the lacrimal glands and tears of NOD mice (a murine model of SS), the aim of this study was to explore the clinical utility of using tear cathepsin S (CTSS) activity as a biomarker for SS.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A method to measure CTSS activity in tears eluted from Schirmer's test strips was developed and validated. Schirmer's tests were performed and CTSS activity measurements were obtained in 278 female subjects, including 73 with SS, 79 with rheumatoid arthritis, 40 with systemic lupus erythematosus, 10 with blepharitis, 31 with nonspecific dry eye disease, and 12 with other autoimmune diseases, as well as 33 healthy control subjects.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The median tear CTSS activity in patients with SS was 4.1‐fold higher than that in patients with other autoimmune diseases, 2.1‐fold higher than that in patients with nonspecific dry eye disease, and 41.1‐fold higher than that in healthy control subjects. Tear CTSS levels were equally elevated in patients with primary SS and those with secondary SS, independent of the Schirmer's test strip values or the levels of circulating anti‐SSA or anti‐SSB antibodies.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Markedly high levels of tear CTSS activity are suggestive of SS. CTSS activity in tears can be measured in a simple, quick, economical, and noninvasive manner and may serve as a novel biomarker for autoimmune dacryoadenitis during the diagnostic evaluation for SS.</jats:p></jats:sec>
収録刊行物
-
- Arthritis & Rheumatology
-
Arthritis & Rheumatology 66 (7), 1872-1881, 2014-06-27
Wiley